Shares of Generation Bio Co. (GBIO) are rising more than 25% Thursday morning after the company announced collaboration with Moderna, Inc. (MRNA) to develop non-viral genetic medicines.
As per the agreement, Generation Bio will receive an upfront payment of $40 million in cash, and a $36 million equity investment at a premium over recent share prices, the company said. Generation Bio is also eligible for milestone payments and royalties.
"This collaboration represents a foundational investment in our platform science, both deepening our pipeline of rare and prevalent liver disease programs beyond hemophilia A and accelerating our work to reach outside of the liver with nucleic acid therapies," Commented Phillip Samayoa, Chief Strategy Officer of Generation Bio.
GBIO is at $4.87 currently. It has traded in the range of $3.40-$9.59 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.